ライブ

FierceBiotechASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout FierceBiotechASCO: Revolution Medicines confident in RAS leadership as rivals square up FierceBiotechASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%Endpoints News#ASCO26: Yes, Revolution Medicines' pancreatic cancer data are that good Endpoints News#ASCO26: Summit, Akeso drug reduces death by 34% in China lung cancer study BioPharma DiveAkeso, Summit drug extends survival in closely watched lung cancer trial BioPharma Dive‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer Science Daily BiotechThe ocean's health may depend on a tiny microbe inside fish Thermo FisherIs Thermo Fisher (TMO) Turning AI-Enabled Orbitraps Into a Durable Edge in Life Sciences Tools? - simplywall.st Endpoints News#ASCO26: Personalized cancer vaccines may help brain cancer patients live longer Endpoints News#ASCO26: Grail’s cancer blood test isn’t ready for widespread use, experts say FierceBiotechIn next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach

FierceBiotech 2026年5月31日

ASCO: Lilly exec points to ‘nutty’ 100% response rate for in vivo CAR-T as justifying Kelonia buyout

Kelonia Therapeutics has shared the largest slice of data yet for an in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid t...

Kelonia Therapeutics has shared the largest slice of data yet for an in vivo CAR-T, helping to justify the $3.2 billion price tag that Eli Lilly recently paid to buy the Boston biotech.